Core Laboratories Inc. (FRA:HJ1)
Germany · Delayed Price · Currency is EUR | Market Cap | 474.18M +6.2% |
| Revenue (ttm) | 454.44M +0.3% |
| Net Income | 21.32M -17.8% |
| EPS | 0.46 -16.1% |
| Shares Out | n/a |
| PE Ratio | 22.24 |
| Forward PE | 18.74 |
| Dividend | 0.03 (0.35%) |
| Ex-Dividend Date | Aug 10, 2026 |
| Volume | n/a |
| Open | 9.80 |
| Previous Close | 9.80 |
| Day's Range | 9.80 - 9.80 |
| 52-Week Range | 8.25 - 16.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About Core Laboratories
Core Laboratories Inc. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and natural gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize pr... [Read more]
Financial Performance
In 2025, Core Laboratories's revenue was $526.52 million, an increase of 0.51% compared to the previous year's $523.85 million. Earnings were $29.67 million, a decrease of -5.51%.
Financial numbers in USD Financial StatementsNews
Core Laboratories upgraded to Buy from Hold at Johnson Rice
Johnson Rice upgraded Core Laboratories (CLB) to Buy from Hold with an unchanged price target of $21.
Core Laboratories Earnings Call Transcript: Q2 2026
Q2 2026 saw sequential revenue and margin growth despite geopolitical disruptions, with Production Enhancement outperforming and Reservoir Description impacted by Middle East and Russia/Ukraine conflicts. Guidance projects further sequential growth in Q3, driven by international markets and continued technology adoption.
Core Laboratories Earnings release: Q2 2026
Core Laboratories released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Core Laboratories Quarterly report: Q2 2026
Core Laboratories has published its Q2 2026 quarterly earnings report on July 30, 2026.
Core Laboratories reports Q2 EPS ex-items 11c, consensus 9c
Reports Q2 revenue $124.6M vs. $130.16M last year. CEO Larry Bruno, stated, “Our Q2 results displayed sequential improvement in revenue, operating income and earnings per share despite continued geopo...
Core Laboratories sees Q3 EPS 12c-20c, consensus 16c
Sees Q3 revenue $128.5M-$135.5M, consensus $131.33M.
CORE LAB REPORTS SECOND QUARTER 2026 RESULTS
REVENUE OF $ 124.6 MILLION, UP 2% SEQUENTIALLY AND DOWN 4% YEAR-OVER-YEAR OPERATING INCOME OF $ 9.2 MILLION; EX-ITEMS, $9.4 MILLION, UP 42% SEQUENTIALLY AND DOWN 36% YEAR-OVER-YEAR GAAP EARNINGS PER S...
Core Laboratories price target lowered to $11 from $12 at BofA
BofA lowered the firm’s price target on Core Laboratories (CLB) to $11 from $12 and keeps an Underperform rating on the shares. The firm updated estimates and targets as part…
CORE LABORATORIES ANNOUNCES TIMING OF SECOND QUARTER 2026 EARNINGS RELEASE AND CONFERENCE CALL
HOUSTON, June 30, 2026 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its second quarter 2026 conference call for investors and analysts at 7:30 a.m. CDT / 8:30 a.m.
Mobility Global to replace Core Laboratories in S&P 600 at open on 7/2
S&P Global (SPGI) is spinning off Mobility Global (MBGL) in a transaction expected to be completed July 1. Core Laboratories (CLB) is no longer representative of the small-cap market space.
Core Laboratories Earnings Call Transcript: Q1 2026
Q1 2026 results were impacted by Middle East conflict, severe weather, and global supply disruptions, leading to lower revenue and margins. Despite these headwinds, the company maintained shareholder returns and expects modest sequential improvement, with long-term demand supported by global energy trends.
Core Laboratories Earnings release: Q1 2026
Core Laboratories released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Core Laboratories Quarterly report: Q1 2026
Core Laboratories has published its Q1 2026 quarterly earnings report on April 30, 2026.
Core Laboratories reports Q1 EPS 6c, consensus 11c
Reports Q1 revenue $121.8M, consensus $124.9M. Core’s CEO, Larry Bruno, stated, “First and foremost, our thoughts remain with our employees and their families across our Middle East operations during ...
Core Laboratories sees Q2 EPS 6c-12c, two estimates 14c
Sees Q2 revenue $123M-$131M, two estimates $127.9M
CORE LAB REPORTS FIRST QUARTER 2026 RESULTS
REVENUE OF $121.8 MILLION, DOWN 12% SEQUENTIALLY AND FLAT YEAR-OVER-YEAR OPERATING INCOME OF $1.9 MILLION; EX-ITEMS, $6.6 MILLION, DOWN 58% SEQUENTIALLY AND 44% YEAR-OVER-YEAR GAAP LOSS PER SHARE OF $...
Core Laboratories Proxy statement: Proxy filing
Core Laboratories filed a proxy statement on March 31, 2026, providing details for shareholder voting and corporate governance matters.
Core Laboratories Proxy statement: Proxy filing
Core Laboratories filed a proxy statement on March 31, 2026, providing details for shareholder voting and corporate governance matters.
Core Laboratories sees Q1 EPS 5c-7c, two estimates 15c
Sees Q1 revenue $119M-$123M, two estimates $125.4M. The company states: “At this time, due to regional instability, including client-driven project delays, travel constraints, and supply-chain disrupt...
Core Laboratories down 5% at $16.00 after Q1 pre-announcement
17:03 EDT Core Laboratories (CLB) down 5% at $16.00 after Q1 pre-announcement
CORE LAB ANNOUNCES IMPACT OF THE MIDDLE EAST CONFLICT TO FIRST QUARTER 2026 GUIDANCE
HOUSTON, March 23, 2026 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company") continues to evaluate and monitor the evolving geopolitical conflict in the Middle E...
Core Laboratories Earnings Call Transcript: Q4 2025
Fourth quarter revenue rose 3% sequentially and 7% year-over-year, with strong international demand offsetting US softness. Margins were pressured by tariffs, bad debt, and weather disruptions, but capital discipline and share buybacks continued. Guidance for Q1 2026 anticipates revenue of $124–$130 million and EPS of $0.11–$0.15.
Core Laboratories Earnings release: Q4 2025
Core Laboratories released its Q4 2025 earnings on February 5, 2026, summarizing the period's financial results.
Core Laboratories Annual report: Q4 2025
Core Laboratories has published its Q4 2025 annual report on February 5, 2026.
Core Laboratories Annual report: Q4 2025
Core Laboratories has published its Q4 2025 annual report on February 5, 2026.